149 related articles for article (PubMed ID: 26668120)
1. Thyroid cancer in 2015: Molecular landscape of thyroid cancer continues to be deciphered.
Nikiforov YE
Nat Rev Endocrinol; 2016 Feb; 12(2):67-8. PubMed ID: 26668120
[No Abstract] [Full Text] [Related]
2. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract][Full Text] [Related]
3. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
5. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
6. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?
Marchand L; Nozières C; Walter T; Descotes F; Decaussin-Petrucci M; Joly MO; Lapras V; Bournaud C; Borson-Chazot F
Acta Oncol; 2016 Aug; 55(8):1064-6. PubMed ID: 27173015
[No Abstract] [Full Text] [Related]
11. [Oncogenes and thyroid tumors].
Lacroix L; Soria JC; Bidart JM; Schlumberger M
Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma.
Rushton S; Burghel G; Wallace A; Nonaka D
Histopathology; 2016 Sep; 69(3):524-6. PubMed ID: 26987976
[No Abstract] [Full Text] [Related]
13. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
Salvatore G; Chiappetta G; Nikiforov YE; Decaussin-Petrucci M; Fusco A; Carney JA; Santoro M
Eur J Cancer; 2005 Mar; 41(5):816-21. PubMed ID: 15763659
[TBL] [Abstract][Full Text] [Related]
14. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
15. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
16. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis.
Pak K; Suh S; Kim SJ; Kim IJ
Thyroid; 2015 Jan; 25(1):63-70. PubMed ID: 25244593
[TBL] [Abstract][Full Text] [Related]
18. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of thyroid cancer: diagnostic and clinical implications.
Fagin JA; Mitsiades N
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):955-69. PubMed ID: 19041825
[TBL] [Abstract][Full Text] [Related]
20. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
[Next] [New Search]
